Technical Analysis for AEZS - AEterna Zentaris Inc.

Grade Last Price % Change Price Change
C 1.17 4.46% 0.05
AEZS closed up 4.46 percent on Friday, February 26, 2021, on 46 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Down
Historical AEZS trend table...

Date Alert Name Type % Chg
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 4.46%
Wide Bands Range Expansion 4.46%
Oversold Stochastic Weakness 4.46%
Narrow Range Bar Range Contraction -2.50%
Wide Bands Range Expansion -2.50%
Oversold Stochastic Weakness -2.50%
Doji - Bullish? Reversal 0.00%
Older End-of-Day Signals for AEZS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

AEterna Zentaris Inc. Description

Aeterna Zentaris Inc. a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in Switzerland, the United States, and Japan. It markets Cetrotide, a luteinizing hormone-releasing hormone antagonist treatment for in vitro fertilization. The company's product pipeline includes AEZS-108, which is in Phase III clinical trial for the treatment of endometrial cancer, as well as in Phase II clinical trial to treat triple-negative breast, ovarian, castration and taxane resistant prostate, and refractory bladder cancers; and AEZS-130, an oral diagnostic test that has completed Phase III clinical trial for adult growth hormone deficiency, as well as in Phase IIA clinical trial for the treatment of cancer-induced cachexia. Its product pipeline also comprise Ozarelix, which is in Phase II clinical trial for the treatment of prostate cancer; Perifosine that is in Phase I/II clinical trials for the treatment of neuroblastoma, glioma, and pediatric solid tumors; and AEZS-112 an oral anticancer agent, which has completed Phase I clinical trial for the treatment of solid tumors and lymphoma. In addition, the company's products in preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate for the treatment of prostate cancer; AEZS-129, 134, and 136 PI3K/Erk inhibitors for oncology; and AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Solid Tumors Treatment Of Cancer Oncology Lymphoma Prostate Cancer Blastoma In Vitro Peptides Bladder Cancer Growth Hormone Cachexia Endometrial Cancer Glioma Neuroblastoma Gnrh Antagonists In Vitro Fertilization Anthracyclines Bladder Cancers Ozarelix Treatment Of Prostate Cancer

Is AEZS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.62
52 Week Low 0.29
Average Volume 19,151,771
200-Day Moving Average 0.64
50-Day Moving Average 0.91
20-Day Moving Average 1.45
10-Day Moving Average 1.42
Average True Range 0.27
ADX 51.81
+DI 34.39
-DI 21.94
Chandelier Exit (Long, 3 ATRs ) 2.80
Chandelier Exit (Short, 3 ATRs ) 1.48
Upper Bollinger Band 2.64
Lower Bollinger Band 0.26
Percent B (%b) 0.38
BandWidth 164.07
MACD Line 0.09
MACD Signal Line 0.19
MACD Histogram -0.1037
Fundamentals Value
Market Cap 73.33 Million
Num Shares 62.7 Million
EPS -0.75
Price-to-Earnings (P/E) Ratio -1.56
Price-to-Sales 9.55
Price-to-Book 1.70
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.44
Resistance 3 (R3) 1.43 1.34 1.40
Resistance 2 (R2) 1.34 1.27 1.34 1.38
Resistance 1 (R1) 1.25 1.23 1.30 1.26 1.36
Pivot Point 1.16 1.16 1.18 1.16 1.16
Support 1 (S1) 1.07 1.09 1.12 1.08 0.98
Support 2 (S2) 0.98 1.05 0.98 0.96
Support 3 (S3) 0.89 0.98 0.95
Support 4 (S4) 0.90